Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
McKinsey
Colorcon
McKesson
Merck

Last Updated: May 20, 2022

ADDERALL XR 15 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Adderall Xr 15, and when can generic versions of Adderall Xr 15 launch?

Adderall Xr 15 is a drug marketed by Takeda Pharms Usa and is included in one NDA.

The generic ingredient in ADDERALL XR 15 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.

Drug patent expirations by year for ADDERALL XR 15
Recent Clinical Trials for ADDERALL XR 15

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of California, Los AngelesEarly Phase 1
University of WyomingPhase 2
Jeffrey NewcornPhase 4

See all ADDERALL XR 15 clinical trials

US Patents and Regulatory Information for ADDERALL XR 15

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa ADDERALL XR 15 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-006 May 22, 2002 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ADDERALL XR 15

International Patents for ADDERALL XR 15

See the table below for patents covering ADDERALL XR 15 around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 1123087 SYSTEME D'ADMINISTRATION DE MEDICAMENTS PAR DOSES PULSEES PAR VOIE ORALE (ORAL PULSED DOSE DRUG DELIVERY SYSTEM) See Plans and Pricing
Spain 2323910 See Plans and Pricing
Japan 2008303223 ORAL PULSED DOSE DRUG DELIVERY SYSTEM See Plans and Pricing
Australia 1214500 See Plans and Pricing
Germany 69940673 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Johnson and Johnson
AstraZeneca
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.